Psoriasis

Summary

Psoriasis (MONDO:0005083) is a disease with 75 cohort genes (1,921 GWAS associations across 87 studies) and 1,154 clinical trials. The dominant Reactome pathway is TNFs bind their physiological receptors (8 cohort genes). Top therapeutic interventions include etanercept, cravacitinib, and calcipotriene.

At a glance

• Cohort genes: 75
• GWAS associations: 1,921
• ClinVar variants: 2
• Clinical trials: 1,154

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	psoriasis
Mondo ID	MONDO:0005083
EFO	EFO:0000676
MeSH	D011565
OMIM	177900
DOID	DOID:8893
ICD-10-CM	L40
ICD-11	63698555
NCIT	C3346
SNOMED CT	9014002
UMLS	C0033860
MedGen	10997
Is cancer (heuristic)	no

Data availability: 2 ClinVar variants · 1,921 GWAS associations (87 studies) · 9 cell lines.

Disease family

An umbrella term covering 3 Mondo subtypes.

Classification path: disease › human disease › disease by body system or component › integumentary system disorder › skin disorder › dermatitis › psoriasis

Related subtypes (32): spongiotic dermatitis, atopic eczema, contact dermatitis, urticaria, acneiform dermatitis, acrodermatitis, folliculitis, granuloma annulare, granulomatous dermatitis, lichen planus, neurodermatitis, neurotic excoriation, parapsoriasis, pityriasis rosea, seborrheic dermatitis, acanthosis nigricans, dermatosis papulosa nigra, lichen sclerosus et atrophicus, vitiligo, acne, porphyria cutanea tarda, dermatomyositis, acute generalized exanthematous pustulosis, hydroa vacciniforme, autoimmune bullous skin disease, cutaneous vasculitis, skin infection, intertrigo, lipodermatosclerosis, exfoliative dermatitis, radiodermatitis, food dermatitis

Subtypes (3): psoriasis 2, pustular psoriasis, guttate psoriasis

Genetics & variants

GWAS landscape

1,921 GWAS associations across 87 studies. Top hits map to 27 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
rs5743293	1e-320	NOD2, CYLD-AS1	?
rs10484554	2e-302	LINC02571 - HLA-B	T	1.67
rs13214872	2e-302	RPL3P2 - WASF5P	G	1.67
rs1265181	2e-208	PSORS1C3 - HCG27	?	22.62
rs80174646	1e-143	IL23R	?
rs12191877	1e-100	RPL3P2 - WASF5P	T	2.64
rs7517847	1e-98	IL23R, C1orf141	?
rs2066845	6e-94	NOD2	?
chr5: 158829527	3e-84		A	0.53
rs1992661	1e-74	RNU1-150P - TTC33	?
rs35300242	5e-67	ATG16L1	?
rs35198068	5e-65	TCF7L2	C	1.21
rs6426833	7e-62	RNF186-AS1 - OTUD3	?
chr5: 150469973	1e-58		A	0.49
rs12188300	2e-56	IL12B-AS1	T	1.31
rs17622378	2e-55	IRF1, CARINH	?
rs3197999	7e-55	MST1	?
rs9977672	5e-54	LINC02940 - RPL23AP12	?
rs469758	6e-54	ERAP1	?
rs35960711	4e-53	SCRN1	G	1.58
rs4672505	2e-52	RN7SL51P - RN7SL18P	?
rs10748781	6e-51	LINC01475	?
rs62377586	3e-50	IL12B-AS1	G	1.18
rs1634774	7e-49	LINC02571 - HLA-B	?	0.48
rs10995271	3e-48	LINC02929 - ALDH7A1P4	?
rs2357623	4e-48	NKD1 - SNX20	?
rs9368611	2e-46	HLA-F-AS1	?	0.64
rs9380151	3e-46	POLR1HASP, POLR1HASP	?	0.62
rs33980500	4e-45	TRAF3IP2-AS1, TRAF3IP2	T	1.52
rs10870077	6e-45	CARD9	?

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST90019016	Stuart PE	2021	15,967	28,194	Transethnic analysis of psoriasis susceptibility in South Asians and Europeans enhances fine-mapping in the MHC and genomewide.
GCST90019017	Stuart PE	2021	15,967	28,194	Transethnic analysis of psoriasis susceptibility in South Asians and Europeans enhances fine-mapping in the MHC and genomewide.
GCST005321	Broce I	2018	12,577	23,475	Immune-related genetic enrichment in frontotemporal dementia: An analysis of genome-wide association studies.
GCST004346	Tsoi LC	2017	11,988	275,335	Large scale meta-analysis characterizes genetic architecture for common psoriasis associated variants.
GCST008479	Zuo X	2015	11,245	11,177	Whole-exome SNP array identifies 15 new susceptibility loci for psoriasis.
GCST90244705	Patrick MT	2022	11,024	139,840	Shared genetic risk factors and causal association between psoriasis and coronary artery disease.
GCST011990	Patrick MT	2020	11,024	840,342	Causal relationship and shared genetic loci between psoriasis and type 2 diabetes through trans-disease meta-analysis.
GCST011991	Patrick MT	2020	11,024	840,342	Causal relationship and shared genetic loci between psoriasis and type 2 diabetes through trans-disease meta-analysis.
GCST011109	Yang C	2019	10,668	10,679	Exome-Wide Rare Loss-of-Function Variant Enrichment Study of 21,347 Han Chinese Individuals Identifies Four Susceptibility Genes for Psoriasis.
GCST005527	Tsoi LC	2012	10,588	22,806	Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	5
Tier 2: splice/UTR	0
Tier 3: regulatory	3
Tier 4: intronic/intergenic	42

MAF distribution

Bucket	Variants
common (>=0.05)	40
low_freq (0.01-0.05)	0
rare (<0.01)	0
unknown	10

Functional consequences

Consequence	Count
intron_variant	22
intergenic_variant	14
unknown	5
missense_variant	4
regulatory_region_variant	2
frameshift_variant	1
TF_binding_site_variant	1
non_coding_transcript_exon_variant	1

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
chr6: 30916259								Tier 4: intronic/intergenic
rs4406273	6	31298313	G>A,T	0.092	intron_variant	LINC02571		Tier 4: intronic/intergenic
rs5743293	16	50729868			frameshift_variant	NOD2, CYLD-AS1	1e-320	Tier 1: coding
rs10484554	6	31306778	C>T	0.05	intron_variant	LINC02571 - HLA-B	2e-302	Tier 4: intronic/intergenic
rs13214872	6	31287231	C>G	0.05	intron_variant	RPL3P2 - WASF5P	2e-302	Tier 4: intronic/intergenic
rs1265181	6	31188008	G>C	0.05	intron_variant	PSORS1C3 - HCG27	2e-208	Tier 4: intronic/intergenic
rs80174646	1	67242472	G>T	0.05	intron_variant	IL23R	1e-143	Tier 4: intronic/intergenic
rs12191877	6	31285148	C>T	0.15	intron_variant	RPL3P2 - WASF5P	1e-100	Tier 4: intronic/intergenic
rs7517847	1	67215986	T>A,C,G	0.05	intron_variant	IL23R, C1orf141	1e-98	Tier 4: intronic/intergenic
rs2066845	16	50722629	G>C,T		missense_variant	NOD2	6e-94	Tier 1: coding
chr5: 158829527							3e-84	Tier 4: intronic/intergenic
rs1992661	5	40414887	G>A	0.05	intron_variant	RNU1-150P - TTC33	1e-74	Tier 4: intronic/intergenic
rs35300242	2	233260144	G>A,C	0.05	intron_variant	ATG16L1	5e-67	Tier 4: intronic/intergenic
rs35198068	10	112995025	T>C	0.05	intron_variant	TCF7L2	5e-65	Tier 4: intronic/intergenic
rs6426833	1	19845367	G>A,C,T	0.05	TF_binding_site_variant	RNF186-AS1 - OTUD3	7e-62	Tier 3: regulatory
chr5: 150469973							1e-58	Tier 4: intronic/intergenic
rs12188300	5	159402519	A>G,T	0.05	intergenic_variant	IL12B-AS1	2e-56	Tier 4: intronic/intergenic
rs17622378	5	132442760	A>G	0.05	intron_variant	IRF1, CARINH	2e-55	Tier 4: intronic/intergenic
rs3197999	3	49684099	G>A,C,T	0.05	missense_variant	MST1	7e-55	Tier 1: coding
rs9977672	21	39091357	G>A	0.05	intergenic_variant	LINC02940 - RPL23AP12	5e-54	Tier 4: intronic/intergenic
rs469758	5	96786011	C>T	0.05	intron_variant	ERAP1	6e-54	Tier 4: intronic/intergenic
rs35960711	7	29940855	C>A,T	0.05	missense_variant	SCRN1	4e-53	Tier 1: coding
rs4672505	2	62333197	A>C,G,T	0.05	intron_variant	RN7SL51P - RN7SL18P	2e-52	Tier 4: intronic/intergenic
rs10748781	10	99523573	C>A,G	0.05	non_coding_transcript_exon_variant	LINC01475	6e-51	Tier 4: intronic/intergenic
rs62377586	5	159339014	G>A	0.05	intergenic_variant	IL12B-AS1	3e-50	Tier 4: intronic/intergenic
rs1634774	6	31335498	A>G	0.05	intron_variant	LINC02571 - HLA-B	7e-49	Tier 4: intronic/intergenic
rs10995271	10	62678726	G>A,C	0.05	intergenic_variant	LINC02929 - ALDH7A1P4	3e-48	Tier 4: intronic/intergenic
rs2357623	16	50660100	A>G,T	0.05	intergenic_variant	NKD1 - SNX20	4e-48	Tier 4: intronic/intergenic
rs9368611	6	29772040	A>C		intron_variant	HLA-F-AS1	2e-46	Tier 4: intronic/intergenic
rs9380151	6	30052051	T>C	0.05	intron_variant	POLR1HASP, POLR1HASP	3e-46	Tier 4: intronic/intergenic

ClinVar germline variants

2 retrieved; paginated sample, class counts are floors:

1 likely pathogenic, 1 benign/likely benign

ClinVar	Variant (HGVS)	Gene	Classification	Review
1691222	NM_014339.7(IL17RA):c.1173C>G (p.Tyr391Ter)	IL17RA	Likely pathogenic	no assertion criteria provided
97813	NM_001375808.2(LPIN2):c.1159A>G (p.Lys387Glu)	LPIN2	Benign/Likely benign	criteria provided, multiple submitters, no conflicts

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 63 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
RORC	Orphanet:477857	Mendelian susceptibility to mycobacterial diseases due to complete RORgamma receptor deficiency
RPS26	Orphanet:124	Diamond-Blackfan anemia
RUNX1	Orphanet:102724	Acute myeloid leukemia with t(8;21)(q22;q22) translocation
RUNX1	Orphanet:521	Chronic myeloid leukemia
RUNX1	Orphanet:71290	Familial platelet disorder with associated myeloid malignancy
RUNX1	Orphanet:98850	Aggressive systemic mastocytosis
SON	Orphanet:500150	ZTTK syndrome
BTD	Orphanet:79241	Biotinidase deficiency
STAT2	Orphanet:431166	Primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection
STAT3	Orphanet:2314	Autosomal dominant hyper-IgE syndrome due to STAT3 deficiency
STAT3	Orphanet:438159	STAT3-related early-onset multisystem autoimmune disease
STAT3	Orphanet:512017	Chronic lymphoproliferative disorder of natural killer cells
STAT3	Orphanet:520	Acute promyelocytic leukemia
STAT3	Orphanet:667662	Breast implant-associated anaplastic large cell lymphoma
STAT3	Orphanet:86872	T-cell large granular lymphocyte leukemia
STAT3	Orphanet:99885	Isolated permanent neonatal diabetes mellitus
STK11	Orphanet:2869	Peutz-Jeghers syndrome
SUOX	Orphanet:99731	Isolated sulfite oxidase deficiency
TGM3	Orphanet:1410	Uncombable hair syndrome
MYRF	Orphanet:647811	Cardiac-urogenital syndrome
TLR4	Orphanet:117	Behçet disease
TNFAIP3	Orphanet:536	Systemic lupus erythematosus
TNFAIP3	Orphanet:674762	Early-onset autoinflammatory syndrome due to A20 haploinsufficiency
TNFRSF1A	Orphanet:32960	Tumor necrosis factor receptor 1 associated periodic syndrome
TNFRSF1A	Orphanet:329967	Intermittent hydrarthrosis
CD40	Orphanet:101090	Hyper-IgM syndrome type 3
TNFRSF9	Orphanet:664726	EBV-induced lymphoproliferative disease due to CD137 deficiency
TNFSF15	Orphanet:186	Primary biliary cholangitis
CD40LG	Orphanet:101088	X-linked hyper-IgM syndrome
FASLG	Orphanet:3261	Autoimmune lymphoproliferative syndrome
TSC1	Orphanet:210159	Adult hepatocellular carcinoma
TSC1	Orphanet:269008	Isolated focal cortical dysplasia type IIb
TSC1	Orphanet:538	Lymphangioleiomyomatosis
TSC1	Orphanet:805	Tuberous sclerosis complex
TYK2	Orphanet:300865	Primary cutaneous anaplastic large cell lymphoma
TYK2	Orphanet:331226	Susceptibility to infection due to TYK2 deficiency
TYK2	Orphanet:98842	Lymphomatoid papulosis
TYRP1	Orphanet:79433	Oculocutaneous albinism type 3
UBE2L3	Orphanet:536	Systemic lupus erythematosus
ACTA2	Orphanet:2573	Moyamoya disease
ACTA2	Orphanet:404463	Multisystemic smooth muscle dysfunction syndrome
ACTA2	Orphanet:91387	Familial thoracic aortic aneurysm and aortic dissection
IKZF3	Orphanet:67038	B-cell chronic lymphocytic leukemia
IKZF3	Orphanet:699590	Immune dysregulation with immunodeficiency due to AIOLOS haploinsufficiency
IKZF3	Orphanet:699593	Combined immunodeficiency-lymphopenia-cancer predisposing syndrome due to AIOLOS deficiency
TRAF3IP2	Orphanet:1334	Chronic mucocutaneous candidiasis
ANO3	Orphanet:420485	Cranio-cervical dystonia with laryngeal and upper-limb involvement
BACH2	Orphanet:714472	Inflammatory bowel disease-autoimmunity-sinopulmonary infections-lymphadenopathy syndrome
LPIN2	Orphanet:77297	Majeed syndrome
CASR	Orphanet:417	Neonatal severe primary hyperparathyroidism

Cohort genes → proteins

75 cohort genes, 75 distinct canonical proteins.

Evidence partition

Subset	Genes
gwas_only	74
multi_evidence	1

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
RGS6	HGNC:10002	ENSG00000182732	P49758	Regulator of G-protein signaling 6	gwas
RORC	HGNC:10260	ENSG00000143365	P51449	Nuclear receptor ROR-gamma	gwas
RPS26	HGNC:10414	ENSG00000197728	P62854	Small ribosomal subunit protein eS26	gwas
RPS6KA4	HGNC:10433	ENSG00000162302	O75676	Ribosomal protein S6 kinase alpha-4	gwas
RPS6KB1	HGNC:10436	ENSG00000108443	P23443	Ribosomal protein S6 kinase beta-1	gwas
RUNX1	HGNC:10471	ENSG00000159216	Q01196	Runt-related transcription factor 1	gwas
RUNX3	HGNC:10473	ENSG00000020633	Q13761	Runt-related transcription factor 3	gwas
CCL21	HGNC:10620	ENSG00000137077	O00585	C-C motif chemokine 21	gwas
XCL1	HGNC:10645	ENSG00000143184	P47992	Lymphotactin	gwas
SDC4	HGNC:10661	ENSG00000124145	P31431	Syndecan-4	gwas
BRAP	HGNC:1099	ENSG00000089234	Q7Z569	BRCA1-associated protein	gwas
SLIT1	HGNC:11085	ENSG00000187122	O75093	Slit homolog 1 protein	gwas
SNAI1	HGNC:11128	ENSG00000124216	O95863	Zinc finger protein SNAI1	gwas
BSN	HGNC:1117	ENSG00000164061	Q9UPA5	Protein bassoon	gwas
SON	HGNC:11183	ENSG00000159140	P18583	Protein SON	gwas
BTD	HGNC:1122	ENSG00000169814	P43251	Biotinidase	gwas
SPRR1B	HGNC:11260	ENSG00000169469	P22528	Cornifin-B	gwas
SPRR3	HGNC:11268	ENSG00000163209	Q9UBC9	Small proline-rich protein 3	gwas
STAT2	HGNC:11363	ENSG00000170581	P52630	Signal transducer and activator of transcription 2	gwas
STAT3	HGNC:11364	ENSG00000168610	P40763	Signal transducer and activator of transcription 3	gwas
STK11	HGNC:11389	ENSG00000118046	Q15831	Serine/threonine-protein kinase STK11	gwas
SUOX	HGNC:11460	ENSG00000139531	P51687	Sulfite oxidase, mitochondrial	gwas
TARBP1	HGNC:11568	ENSG00000059588	Q13395	tRNA (guanosine(18)-2’-O)-methyltransferase TARBP1	gwas
ELOA	HGNC:11620	ENSG00000011007	Q14241	Elongin-A	gwas
ACO1	HGNC:117	ENSG00000122729	P21399	Cytoplasmic aconitate hydratase	gwas
TGM3	HGNC:11779	ENSG00000125780	Q08188	Protein-glutamine gamma-glutamyltransferase E	gwas
MYRF	HGNC:1181	ENSG00000124920	Q9Y2G1	Myelin regulatory factor	gwas
TLR4	HGNC:11850	ENSG00000136869	O00206	Toll-like receptor 4	gwas
TNFAIP3	HGNC:11896	ENSG00000118503	P21580	Tumor necrosis factor alpha-induced protein 3	gwas
TNFRSF14	HGNC:11912	ENSG00000157873	Q92956	Tumor necrosis factor receptor superfamily member 14	gwas
TNFRSF1A	HGNC:11916	ENSG00000067182	P19438	Tumor necrosis factor receptor superfamily member 1A	gwas
CD40	HGNC:11919	ENSG00000101017	P25942	Tumor necrosis factor receptor superfamily member 5	gwas
TNFRSF6B	HGNC:11921	ENSG00000243509	O95407	Tumor necrosis factor receptor superfamily member 6B	gwas
TNFRSF9	HGNC:11924	ENSG00000049249	Q07011	Tumor necrosis factor receptor superfamily member 9	gwas
TNFSF15	HGNC:11931	ENSG00000181634	O95150	Tumor necrosis factor ligand superfamily member 15	gwas
TNFSF18	HGNC:11932	ENSG00000120337	Q9UNG2	Tumor necrosis factor ligand superfamily member 18	gwas
CD40LG	HGNC:11935	ENSG00000102245	P29965	CD40 ligand	gwas
FASLG	HGNC:11936	ENSG00000117560	P48023	Tumor necrosis factor ligand superfamily member 6	gwas
TNFSF8	HGNC:11938	ENSG00000106952	P32971	Tumor necrosis factor ligand superfamily member 8	gwas
TNP2	HGNC:11952	ENSG00000178279	Q05952	Nuclear transition protein 2	gwas
TSC1	HGNC:12362	ENSG00000165699	Q92574	Hamartin	gwas
EIPR1	HGNC:12383	ENSG00000032389	Q53HC9	EARP and GARP complex-interacting protein 1	gwas
TYK2	HGNC:12440	ENSG00000105397	P29597	Non-receptor tyrosine-protein kinase TYK2	gwas
TYRP1	HGNC:12450	ENSG00000107165	P17643	5,6-dihydroxyindole-2-carboxylic acid oxidase	gwas
UBASH3A	HGNC:12462	ENSG00000160185	P57075	Ubiquitin-associated and SH3 domain-containing protein A	gwas
UBE2L3	HGNC:12488	ENSG00000185651	P68036	Ubiquitin-conjugating enzyme E2 L3	gwas
ACTA2	HGNC:130	ENSG00000107796	P62736	Actin, aortic smooth muscle	gwas
RNF114	HGNC:13094	ENSG00000124226	Q9Y508	E3 ubiquitin-protein ligase RNF114	gwas
SIRAL2	HGNC:1313	ENSG00000100376	Q9NWS6	Protein FAM118A	gwas
IKZF3	HGNC:13178	ENSG00000161405	Q9UKT9	Zinc finger protein Aiolos	gwas

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
RGS6	Regulator of G-protein signaling 6	Regulates G protein-coupled receptor signaling cascades.
RORC	Nuclear receptor ROR-gamma	Nuclear receptor that binds DNA as a monomer to ROR response elements (RORE) containing a single core motif half-site 5’-AGGTCA-3’ preceded by a short A-T-rich sequence.
RPS26	Small ribosomal subunit protein eS26	Component of the small ribosomal subunit.
RPS6KA4	Ribosomal protein S6 kinase alpha-4	Serine/threonine-protein kinase that is required for the mitogen or stress-induced phosphorylation of the transcription factors CREB1 and ATF1 and for the regulation of the transcription factor RELA, and that contributes to gene activation…
RPS6KB1	Ribosomal protein S6 kinase beta-1	Serine/threonine-protein kinase that acts downstream of mTOR signaling in response to growth factors and nutrients to promote cell proliferation, cell growth and cell cycle progression.
RUNX1	Runt-related transcription factor 1	Forms the heterodimeric complex core-binding factor (CBF) with CBFB.
RUNX3	Runt-related transcription factor 3	Forms the heterodimeric complex core-binding factor (CBF) with CBFB.
CCL21	C-C motif chemokine 21	Inhibits hemopoiesis and stimulates chemotaxis.
XCL1	Lymphotactin	Chemotactic activity for lymphocytes but not for monocytes or neutrophils.
SDC4	Syndecan-4	Cell surface proteoglycan which regulates exosome biogenesis in concert with SDCBP and PDCD6IP.
BRAP	BRCA1-associated protein	Negatively regulates MAP kinase activation by limiting the formation of Raf/MEK complexes probably by inactivation of the KSR1 scaffold protein.
SLIT1	Slit homolog 1 protein	Thought to act as molecular guidance cue in cellular migration, and function appears to be mediated by interaction with roundabout homolog receptors.
SNAI1	Zinc finger protein SNAI1	Involved in induction of the epithelial to mesenchymal transition (EMT), formation and maintenance of embryonic mesoderm, growth arrest, survival and cell migration.
BSN	Protein bassoon	Scaffold protein of the presynaptic cytomatrix at the active zone (CAZ) which is the place in the synapse where neurotransmitter is released.
SON	Protein SON	RNA-binding protein that acts as a mRNA splicing cofactor by promoting efficient splicing of transcripts that possess weak splice sites.
BTD	Biotinidase	Catalytic release of biotin from biocytin, the product of biotin-dependent carboxylases degradation.
SPRR1B	Cornifin-B	Cross-linked envelope protein of keratinocytes.
SPRR3	Small proline-rich protein 3	Cross-linked envelope protein of keratinocytes.
STAT2	Signal transducer and activator of transcription 2	Signal transducer and activator of transcription that mediates signaling by type I interferons (IFN-alpha and IFN-beta).
STAT3	Signal transducer and activator of transcription 3	Signal transducer and transcription activator that mediates cellular responses to interleukins, KITLG/SCF, LEP and other growth factors.
STK11	Serine/threonine-protein kinase STK11	Tumor suppressor serine/threonine-protein kinase that controls the activity of AMP-activated protein kinase (AMPK) family members, thereby playing a role in various processes such as cell metabolism, cell polarity, apoptosis and DNA damage…
SUOX	Sulfite oxidase, mitochondrial	Catalyzes the oxidation of sulfite to sulfate, the terminal reaction in the oxidative degradation of sulfur-containing amino acids.
TARBP1	tRNA (guanosine(18)-2’-O)-methyltransferase TARBP1	S-adenosyl-L-methionine-dependent 2’-O-ribose methyltransferase that catalyzes the formation of 2’-O-methylguanosine at position 18 (Gm18) in a subset of tRNA.
ELOA	Elongin-A	SIII, also known as elongin, is a general transcription elongation factor that increases the RNA polymerase II transcription elongation past template-encoded arresting sites.
ACO1	Cytoplasmic aconitate hydratase	Bifunctional iron sensor that switches between 2 activities depending on iron availability.
TGM3	Protein-glutamine gamma-glutamyltransferase E	Catalyzes the calcium-dependent formation of isopeptide cross-links between glutamine and lysine residues in various proteins, as well as the conjugation of polyamines to proteins.
MYRF	Myelin regulatory factor	Constitutes a precursor of the transcription factor.
TLR4	Toll-like receptor 4	Transmembrane receptor that functions as a pattern recognition receptor recognizing pathogen- and damage-associated molecular patterns (PAMPs and DAMPs) to induce innate immune responses via downstream signaling pathways.
TNFAIP3	Tumor necrosis factor alpha-induced protein 3	Ubiquitin-editing enzyme that contains both ubiquitin ligase and deubiquitinase activities.
TNFRSF14	Tumor necrosis factor receptor superfamily member 14	Receptor for four distinct ligands: The TNF superfamily members TNFSF14/LIGHT and homotrimeric LTA/lymphotoxin-alpha and the immunoglobulin superfamily members BTLA and CD160, altogether defining a complex stimulatory and inhibitory signal…
TNFRSF1A	Tumor necrosis factor receptor superfamily member 1A	Receptor for TNFSF2/TNF and homotrimeric TNFSF1/lymphotoxin-alpha.
CD40	Tumor necrosis factor receptor superfamily member 5	Receptor for TNFSF5/CD40LG.
TNFRSF6B	Tumor necrosis factor receptor superfamily member 6B	Decoy receptor that can neutralize the cytotoxic ligands TNFS14/LIGHT, TNFSF15 and TNFSF6/FASL.
TNFRSF9	Tumor necrosis factor receptor superfamily member 9	Receptor for TNFSF9/4-1BBL.
TNFSF15	Tumor necrosis factor ligand superfamily member 15	Receptor for TNFRSF25 and TNFRSF6B.
TNFSF18	Tumor necrosis factor ligand superfamily member 18	Cytokine that binds to TNFRSF18/AITR/GITR.
CD40LG	CD40 ligand	Cytokine that acts as a ligand to CD40/TNFRSF5.
FASLG	Tumor necrosis factor ligand superfamily member 6	Cytokine that binds to TNFRSF6/FAS, a receptor that transduces the apoptotic signal into cells.
TNFSF8	Tumor necrosis factor ligand superfamily member 8	Cytokine that binds to TNFRSF8/CD30.
TNP2	Nuclear transition protein 2	Plays a key role in the replacement of histones to protamine in the elongating spermatids of mammals.
TSC1	Hamartin	Non-catalytic component of the TSC-TBC complex, a multiprotein complex that acts as a negative regulator of the canonical mTORC1 complex, an evolutionarily conserved central nutrient sensor that stimulates anabolic reactions and macromolec…
EIPR1	EARP and GARP complex-interacting protein 1	Acts as a component of endosomal retrieval machinery that is involved in protein transport from early endosomes to either recycling endosomes or the trans-Golgi network.
TYK2	Non-receptor tyrosine-protein kinase TYK2	Tyrosine kinase of the non-receptor type involved in numerous cytokines and interferons signaling, which regulates cell growth, development, cell migration, innate and adaptive immunity.
TYRP1	5,6-dihydroxyindole-2-carboxylic acid oxidase	Plays a role in melanin biosynthesis.
UBASH3A	Ubiquitin-associated and SH3 domain-containing protein A	Interferes with CBL-mediated down-regulation and degradation of receptor-type tyrosine kinases.
UBE2L3	Ubiquitin-conjugating enzyme E2 L3	Ubiquitin-conjugating enzyme E2 that specifically acts with HECT-type and RBR family E3 ubiquitin-protein ligases.
ACTA2	Actin, aortic smooth muscle	Actins are highly conserved proteins that are involved in various types of cell motility and are ubiquitously expressed in all eukaryotic cells.
RNF114	E3 ubiquitin-protein ligase RNF114	E3 ubiquitin-protein ligase that promotes the ubiquitination of various substrates.
IKZF3	Zinc finger protein Aiolos	Transcription factor that plays an important role in the regulation of lymphocyte differentiation.
TRAF3IP2	E3 ubiquitin ligase TRAF3IP2	E3 ubiquitin ligase that catalyzes ‘Lys-63’-linked polyubiquitination of target protein, enhancing protein-protein interaction and cell signaling.

Protein-family classification

Druggable: 20 · Difficult: 17 · Unknown: 38 · Druggable fraction: 0.27

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Kinase	7	2.6×	0.184
Transcription factor	14	1.5×	0.324
Nuclear receptor	1	5.2×	0.590
Complement	1	3.6×	0.612
Enzyme (other)	7	1.1×	0.872
Phosphatase	1	1.1×	0.927
Other/Unknown	38	0.9×	0.927
Scaffold/PPI	3	0.7×	0.927
GPCR	2	0.6×	0.927
Antibody/Immunoglobulin	1	0.4×	0.927

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
RGS6	Other/Unknown	no		DEP_dom, G-protein_gamma-like_dom, RGS
RORC	Nuclear receptor	yes		Nucl_hrmn_rcpt_lig-bd, Znf_hrmn_rcpt, Nuclear_hrmn_rcpt
RPS26	Other/Unknown	no		Ribosomal_eS26, Ribosomal_eS26_sf, Ribosomal_eS26_CS
RPS6KA4	Kinase	yes		Prot_kinase_dom, AGC-kinase_C, Ser/Thr_kinase_AS
RPS6KB1	Kinase	yes	2.7.11.1	Prot_kinase_dom, AGC-kinase_C, Ser/Thr_kinase_AS
RUNX1	Transcription factor	no		AML1_Runt, p53-like_TF_DNA-bd_sf, p53/RUNT-type_TF_DNA-bd_sf
RUNX3	Transcription factor	no		AML1_Runt, p53-like_TF_DNA-bd_sf, p53/RUNT-type_TF_DNA-bd_sf
CCL21	Other/Unknown	no		Chemokine_IL8-like_dom, Chemokine_CC_DCCL, Interleukin_8-like_sf
XCL1	Other/Unknown	no		Chemokine_IL8-like_dom, Chemokine_XCL1/XCL2, Interleukin_8-like_sf
SDC4	Other/Unknown	no		Syndecan, Neurexin-like, Syndecan/Neurexin_dom
BRAP	Transcription factor	no		Znf_UBP, Znf_RING, BRAP2/ETP1_RRM
SLIT1	Other/Unknown	no		EGF-type_Asp/Asn_hydroxyl_site, LRRNT, Cys-rich_flank_reg_C
SNAI1	Transcription factor	no		Znf_C2H2_type, Znf_C2H2_sf,
BSN	Transcription factor	no		Znf_piccolo, Znf_FYVE_PHD, Znf_RING/FYVE/PHD
SON	Scaffold/PPI	no		G_patch_dom, dsRBD_dom,
BTD	Enzyme (other)	yes	3.5.1.12	C-N_Hydrolase, Biotinidase-like_euk, C-N_Hydrolase_sf
SPRR1B	Other/Unknown	no
SPRR3	Other/Unknown	no
STAT2	Transcription factor	no		SH2, STAT, p53-like_TF_DNA-bd_sf
STAT3	Transcription factor	no		SH2, STAT, p53-like_TF_DNA-bd_sf
STK11	Kinase	yes	2.7.11.1	Prot_kinase_dom, Ser/Thr_kinase_AS, Kinase-like_dom_sf
SUOX	Enzyme (other)	yes	1.8.3.1	OxRdtase_Mopterin-bd_dom, Cyt_B5-like_heme/steroid-bd, MoCF_OxRdtse_dimer
TARBP1	Enzyme (other)	yes	2.1.1.34	SpoU_MeTrfase, ARM-type_fold, TARBP1
ELOA	Other/Unknown	no		F-box_dom, TFIIS/CRSP70_N_sub, RNA_pol_II_trans_fac_SIII_A
ACO1	Enzyme (other)	yes	4.2.1.3	AconitaseA/IPMdHydase_ssu_swvl, Acoase/IPM_deHydtase_lsu_aba, Aconitase/IRP2
TGM3	Antibody/Immunoglobulin	yes	2.3.2.13	Transglutaminase_N, Transglutaminase-like, Transglutaminase_C
MYRF	Transcription factor	no		p53-like_TF_DNA-bd_sf, NDT80_DNA-bd_dom, MYRF_C2
TLR4	Other/Unknown	no		TIR_dom, Cys-rich_flank_reg_C, Leu-rich_rpt
TNFAIP3	Transcription factor	no		Znf_A20, OTU_dom, OTU_Deubiquitinase
TNFRSF14	Other/Unknown	no		TNFR/NGFR_Cys_rich_reg, TNFR_14, TNFRSF14/UL144_N
TNFRSF1A	Other/Unknown	no		Death_dom, TNFR/NGFR_Cys_rich_reg, DEATH-like_dom_sf
CD40	Other/Unknown	no		TNFR/NGFR_Cys_rich_reg, TNFR_5, TNFRSF5_N
TNFRSF6B	Other/Unknown	no		TNFR/NGFR_Cys_rich_reg, TNFRSF6B_N, TNFRSF_decoy_receptor
TNFRSF9	Other/Unknown	no		TNFR/NGFR_Cys_rich_reg, Growth_fac_rcpt_cys_sf, TNFR_9
TNFSF15	Other/Unknown	no		TNF_dom, TNF, Tumour_necrosis_fac-like_dom
TNFSF18	Other/Unknown	no		TNF_dom, Tumour_necrosis_fac-like_dom, TNFSF18
CD40LG	Other/Unknown	no		CD40L, TNF_dom, Tumour_necrosis_fac-like_dom
FASLG	Other/Unknown	no		TNF_dom, TNF, Tumour_necrosis_fac-like_dom
TNFSF8	Other/Unknown	no		TNF_dom, Tumour_necrosis_fac-like_dom, TNF_CS
TNP2	Other/Unknown	no		TP2
TSC1	Other/Unknown	no		Hamartin
EIPR1	Scaffold/PPI	no		WD40_rpt, WD40/YVTN_repeat-like_dom_sf, WD40_repeat_CS
TYK2	Kinase	yes	2.7.10.2	FERM_domain, Prot_kinase_dom, SH2
TYRP1	Other/Unknown	no		Tyrosinase_Cu-bd, Di-copper_centre_dom_sf, Tyrosinase/Hemocyanin
UBASH3A	Phosphatase	yes		SH3_domain, UBA-like_sf, His_Pase_superF_clade-1
UBE2L3	Enzyme (other)	yes	2.3.2.23	UBC, UBQ-conjugating_enzyme/RWD, UBQ-conjugating_AS
ACTA2	Other/Unknown	no		Actin, Actin_CS, Actin/actin-like_CS
RNF114	Transcription factor	no		Znf_RING, Di19_Zn-bd, Znf_RING/FYVE/PHD
SIRAL2	Other/Unknown	no		FAM118
IKZF3	Transcription factor	no		Znf_C2H2_type, Znf_C2H2_sf, Ikaros_C2H2-ZF

Expression context

Cohort genes with no expression data: 0.

70 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	1
moderate (6-20)	0
broad (>20)	74
unknown	0

Top tissues across cohort

Tissue	Cohort genes
granulocyte	12
lymph node	9
left testis	8
middle temporal gyrus	6
right testis	6
male germ line stem cell (sensu Vertebrata) in testis	5
cartilage tissue	5
gall bladder	5
right lobe of liver	5
monocyte	5
secondary oocyte	5
cortical plate	4
sural nerve	4
right hemisphere of cerebellum	4
spleen	4
stromal cell of endometrium	4
blood	4
oocyte	4
cerebellar hemisphere	3
olfactory segment of nasal mucosa	3

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
RGS6	185	broad	marker	cortical plate, sural nerve, middle temporal gyrus
RORC	209	broad	marker	gastrocnemius, male germ line stem cell (sensu Vertebrata) in testis, hindlimb stylopod muscle
RPS26	140	ubiquitous	marker	granulocyte, left adrenal gland cortex, mucosa of transverse colon
RPS6KA4	215	ubiquitous	marker	right hemisphere of cerebellum, cerebellar hemisphere, cerebellar cortex
RPS6KB1	275	ubiquitous	marker	endothelial cell, Brodmann (1909) area 23, calcaneal tendon
RUNX1	253	ubiquitous	marker	olfactory segment of nasal mucosa, epithelium of bronchus, mucosa of paranasal sinus
RUNX3	220	broad	marker	granulocyte, buccal mucosa cell, lymph node
CCL21	206	tissue_specific	marker	lymph node, right lobe of thyroid gland, vermiform appendix
XCL1	131	broad	marker	granulocyte, spleen, lymph node
SDC4	290	ubiquitous	marker	olfactory segment of nasal mucosa, nasal cavity epithelium, cartilage tissue
BRAP	286	ubiquitous	marker	left testis, right testis, testis
SLIT1	186	broad	marker	cortical plate, middle temporal gyrus, orbitofrontal cortex
SNAI1	164	ubiquitous	marker	omental fat pad, peritoneum, gall bladder
BSN	156	broad	marker	frontal pole, paraflocculus, middle temporal gyrus
SON	304	ubiquitous	marker	pylorus, tendon of biceps brachii, cardia of stomach
BTD	261	ubiquitous	marker	islet of Langerhans, right lobe of liver, liver
SPRR1B	175	broad	marker	amniotic fluid, gingiva, cervix squamous epithelium
SPRR3	174	broad	marker	lower esophagus mucosa, oral cavity, pharyngeal mucosa
STAT2	277	ubiquitous	marker	granulocyte, stromal cell of endometrium, monocyte
STAT3	301	ubiquitous	marker	type B pancreatic cell, pericardium, lower lobe of lung
STK11	238	ubiquitous	marker	left testis, right testis, hindlimb stylopod muscle
SUOX	267	ubiquitous	marker	right lobe of liver, right adrenal gland, right adrenal gland cortex
TARBP1	290	ubiquitous	marker	right hemisphere of cerebellum, right uterine tube, cerebellar hemisphere
ELOA	289	ubiquitous	marker	buccal mucosa cell, lower lobe of lung, cardia of stomach
ACO1	282	ubiquitous	marker	right lobe of liver, liver, stromal cell of endometrium
TGM3	120	tissue_specific	marker	lower esophagus mucosa, esophagus mucosa, skin of leg
MYRF	223	ubiquitous	marker	middle frontal gyrus, C1 segment of cervical spinal cord, inferior vagus X ganglion
TLR4	233	ubiquitous	marker	monocyte, mononuclear cell, leukocyte
TNFAIP3	274	ubiquitous	marker	vena cava, mucosa of paranasal sinus, vermiform appendix
TNFRSF14	134	ubiquitous	marker	granulocyte, spleen, right uterine tube

Protein interactions among cohort

Intra-cohort edges: 44.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
STAT3	10,108
TLR4	6,974
SNAI1	5,518
RPS6KB1	5,474
TSC1	5,445
CAPZB	5,209
STK11	5,146
RUNX1	4,994
TNFRSF1A	4,523
FASLG	4,373

Intra-cohort edges

A	B	Sources
BACH2	TAGAP	string_interaction
BACH2	UBASH3A	string_interaction
BRAP	TNFAIP3	intact
CCL21	XCL1	biogrid_interaction, intact, string_interaction
CD40	CD40LG	biogrid_interaction, intact, string_interaction
CD40	FASLG	string_interaction
CD40	SLC39A11	intact
CD40	TNFRSF9	string_interaction
CD40	TNFSF8	string_interaction
CD40	TRAF3IP2	biogrid_interaction
CD40LG	TNFSF8	string_interaction
FASLG	SKAP2	intact
FASLG	TNFRSF1A	string_interaction
FASLG	TNFRSF6B	biogrid_interaction, intact, string_interaction
IKBKE	TRAF3IP2	biogrid_interaction
IKZF3	RUNX1	string_interaction
IKZF3	RUNX3	string_interaction
PRM3	TNP2	string_interaction
RNF114	SPATA2	string_interaction
RNF114	TNFAIP3	biogrid_interaction, intact, string_interaction
RNF114	TRAF3IP2	string_interaction
RPS6KB1	TSC1	string_interaction
RUNX1	RUNX3	string_interaction
SPATA2	TNFRSF1A	string_interaction
SPRR3	STK11	intact
SPRR3	TGM3	string_interaction
STAT2	TYK2	intact, string_interaction
STAT3	TYK2	string_interaction
TNFAIP3	TNFRSF1A	biogrid_interaction
TNFAIP3	TRAF3IP2	string_interaction
TNFRSF14	TNFRSF6B	string_interaction
TNFRSF14	TNFSF15	string_interaction
TNFRSF14	TNFSF18	string_interaction
TNFRSF14	TNFSF8	string_interaction
TNFRSF1A	TNFRSF6B	string_interaction
TNFRSF1A	TNFSF15	string_interaction
TNFRSF1A	TNFSF8	string_interaction
TNFRSF6B	TNFSF15	biogrid_interaction, intact, string_interaction
TNFRSF6B	TNFSF8	string_interaction
TNFRSF9	TNFSF18	string_interaction
TNFRSF9	TNFSF8	string_interaction
TNFSF15	TNFSF18	string_interaction
TNFSF15	TNFSF8	string_interaction
TP63	UBASH3A	intact

Structural data

PDB: 49 · AlphaFold-only: 26 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
RPS26	P62854	190
RORC	P51449	161
TYK2	P29597	52
CASR	P41180	31
TP63	Q9H3D4	26
RPS6KB1	P23443	22
UBE2L3	P68036	21
TNFAIP3	P21580	17
TLR4	O00206	15
IL23A	Q9NPF7	15
CD40	P25942	14
TNFRSF9	Q07011	14
TNFRSF1A	P19438	13
TYRP1	P17643	13
B3GNT2	Q9NY97	12
TGM3	Q08188	11
SNAI1	O95863	9
TNFRSF14	Q92956	8
TNFRSF6B	O95407	8
CD40LG	P29965	8
CAPZB	P47756	8
XCL1	P47992	7
TNFSF15	O95150	7
TNFSF18	Q9UNG2	7
STAT2	P52630	6
STAT3	P40763	6
HDAC7	Q8WUI4	6
RUNX1	Q01196	5
CCL21	O00585	5
SDC4	P31431	5

AlphaFold-only cohort genes (top 30 by pLDDT)

Symbol	UniProt	pLDDT
GLYAT	Q6IB77	95.71
ACTA2	P62736	95.43
EIPR1	Q53HC9	89.26
IKBKE	Q14164	88.81
BTD	P43251	86.77
RNF114	Q9Y508	84.23
SIRAL2	Q9NWS6	83.77
SLIT1	O75093	80.28
TNFSF8	P32971	80.07
CHST8	Q9H2A9	79.90
CCHCR1	Q8TD31	79.52
BRAP	Q7Z569	76.92
SLC39A11	Q8N1S5	76.64
ANO3	Q9BYT9	76.30
RPS6KA4	O75676	72.00
SPRR1B	P22528	70.02
FOSL1	P15407	67.32
LPIN2	Q92539	61.12
OR2W5	A6NFC9	60.12
TNP2	Q05952	59.17
KLF13	Q9Y2Y9	58.91
PRM3	Q9NNZ6	58.43
TAGAP	Q8N103	57.36
SPRR3	Q9UBC9	52.87
IKZF3	Q9UKT9	48.06
BSN	Q9UPA5

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 748. Enrichment computed across 250 evidence-associated genes (151 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 151 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
TNFs bind their physiological receptors	8	20.9×	2e-06	TNFRSF14, TNFRSF1A, TNFRSF6B, TNFRSF9, TNFSF15, TNFSF18, FASLG, TNFSF8
Interleukin-23 signaling	4	33.6×	0.001	STAT3, TYK2, IL23A, IL23R
Regulation of TNFR1 signaling	6	8.9×	0.013	TNFAIP3, TNFRSF1A, UBE2L3, IKBKE, SPATA2, CHUK
Interleukin-4 and Interleukin-13 signaling	8	5.5×	0.020	RORC, STAT3, FASLG, TYK2, IL23A, IL23R, SOCS1, FOS
SARS-CoV-1 activates/modulates innate immune responses	5	9.0×	0.032	RUNX1, IKBKE, IFIH1, RIGI, STING1
TNFR1-induced proapoptotic signaling	4	11.6×	0.043	TNFAIP3, TNFRSF1A, IKBKE, SPATA2
Interleukin-20 family signaling	4	11.2×	0.043	STAT2, STAT3, TYK2, IFNLR1
RUNX3 regulates RUNX1-mediated transcription	2	50.4×	0.048	RUNX1, RUNX3
NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10	3	17.4×	0.049	IFIH1, RIGI, CHUK
TRAF3-dependent IRF activation pathway	3	15.1×	0.060	IKBKE, IFIH1, RIGI
TNFR1-induced NF-kappa-B signaling pathway	4	8.9×	0.060	TNFAIP3, TNFRSF1A, SPATA2, CHUK
Dengue virus activates/modulates innate and adaptive immune responses	4	8.9×	0.060	STAT2, IKBKE, IFIH1, STING1
Negative regulators of DDX58/IFIH1 signaling	4	8.6×	0.060	TNFAIP3, IKBKE, IFIH1, RIGI
Evasion by RSV of host interferon responses	4	8.6×	0.060	STAT2, TYK2, IFIH1, RIGI
SARS-CoV-2 activates/modulates innate and adaptive immune responses	7	4.1×	0.076	STAT2, TYK2, IKBKE, IFIH1, RIGI, CHUK, STING1
Formation of the cornified envelope	7	4.1×	0.078	SPRR1B, SPRR3, LCE3D, LIPK, LCE3A, LCE3B, LCE3E
Modulation of host responses by IFN-stimulated genes	3	11.9×	0.083	IFIH1, RIGI, CHUK
Ovarian tumor domain proteases	4	7.4×	0.085	TNFAIP3, TNIP1, IFIH1, RIGI
Signaling by CSF3 (G-CSF)	3	11.3×	0.086	STAT3, TYK2, SOCS1
RUNX3 Regulates Immune Response and Cell Migration	2	25.2×	0.094	RORC, RUNX3
Oncogenic MAPK signaling	4	6.6×	0.111	BRAP, CAMK2G, SPRED2, AGK
Differentiation of naive CD4+ T cells to T helper 2 cells (Th2 cells)	5	4.8×	0.125	KLF13, HDAC7, TBL1XR1, ETS1, FOS
TRAF6 mediated NF-kB activation	3	9.1×	0.137	IFIH1, RIGI, CHUK
Regulation of IFNA/IFNB signaling	3	8.7×	0.141	STAT2, TYK2, SOCS1
Inactivation of CSF3 (G-CSF) signaling	3	8.7×	0.141	STAT3, TYK2, SOCS1
Diseases of signal transduction by growth factor receptors and second messengers	8	3.0×	0.150	BRAP, STAT3, CAMK2G, CD28, CEP43, SPRED2, AGK, TBL1XR1
Defective BTD causes biotidinase deficiency	1	75.6×	0.157	BTD
Defective SLC26A3 causes congenital secretory chloride diarrhea 1 (DIAR1)	1	75.6×	0.157	SLC26A3
FLT3 mutants bind TKIs	1	75.6×	0.157	FLT3
KW2449-resistant FLT3 mutants	1	75.6×	0.157	FLT3

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 219 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
positive regulation of canonical NF-kappaB signal transduction	17	5.6×	2e-05	CCL21, STAT3, TLR4, TNFRSF1A, CD40, TNFSF15, CD40LG, FASLG (+9 more)
positive regulation of interleukin-10 production	7	12.8×	5e-04	XCL1, STAT3, TLR4, CD40LG, IL23A, CD28, INAVA
cell surface receptor signaling pathway via JAK-STAT	8	10.6×	5e-04	STAT2, STAT3, TNFRSF1A, CD40, TYK2, IL23A, IL23R, SOCS1
positive regulation of defense response to virus by host	6	14.4×	0.001	TRAF3IP2, IL23A, IL23R, RIGI, STING1, AIM2
inflammatory response	19	3.3×	0.002	RPS6KA4, CCL21, XCL1, STAT3, TLR4, TNFAIP3, TNFRSF1A, CD40 (+11 more)
positive regulation of T-helper 17 type immune response	4	25.6×	0.003	TYK2, IL23A, CARD9, IL23R
obsolete positive regulation of NF-kappaB transcription factor activity	8	7.5×	0.003	RPS6KA4, TLR4, TNFSF18, CD40LG, CARD9, CARD14, CHUK, AIM2
positive regulation of tumor necrosis factor production	9	6.3×	0.003	STAT3, TLR4, IL23A, CARD9, LRRK2, SPHK2, IFIH1, RIGI (+1 more)
positive regulation of interferon-alpha production	5	14.8×	0.003	TLR4, IFIH1, RIGI, CHUK, TRIM65
positive regulation of inflammatory response	9	6.0×	0.003	STAT3, TLR4, TNFRSF1A, TNFSF18, IL23A, TNIP1, NFKBIZ, ETS1 (+1 more)
T cell costimulation	6	10.3×	0.003	CCL21, TNFRSF14, CD40LG, CD28, KLRK1, EFNB2
interleukin-23-mediated signaling pathway	3	38.5×	0.005	STAT3, TYK2, IL23R
tumor necrosis factor-mediated signaling pathway	6	9.1×	0.005	TNFRSF1A, TNFSF18, TRAF3IP2, CARD14, CHUK, AIM2
keratinization	7	7.5×	0.005	SPRR1B, SPRR3, TGM3, LCE3D, LCE3A, LCE3B, LCE3E
defense response to Gram-negative bacterium	8	6.2×	0.005	TLR4, TNFRSF14, IL23A, IL23R, LCE3A, LCE3B, IRGM, NFKBIZ
cytokine-mediated signaling pathway	9	5.4×	0.005	STAT3, TNFRSF1A, TYK2, FOSL1, IFNLR1, IL23R, SOCS1, NFKBIZ (+1 more)
positive regulation of granulocyte macrophage colony-stimulating factor production	4	18.1×	0.005	IL23A, CARD9, IL23R, RIGI
positive regulation of transcription by RNA polymerase II	31	2.1×	0.006	RPS6KA4, RUNX1, XCL1, STAT2, STAT3, TLR4, TNFRSF1A, CD40 (+23 more)
regulation of type III interferon production	2	77.0×	0.014	IFIH1, RIGI
CD40 signaling pathway	3	23.1×	0.015	CD40, CD40LG, TRAF3IP2
fat pad development	3	23.1×	0.015	CASR, TBL1XR1, FOSL2
regulation of tumor necrosis factor-mediated signaling pathway	4	12.8×	0.015	TNFAIP3, TNFRSF1A, SPATA2, HIPK1
positive regulation of interferon-beta production	5	8.9×	0.015	TLR4, IFIH1, RIGI, TRIM65, STING1
positive regulation of interleukin-12 production	5	8.9×	0.015	TLR4, CD40, CD40LG, IL23A, IL23R
positive regulation of T cell proliferation	6	7.1×	0.015	CD40LG, TYK2, IL23A, CD28, CD6, IL23R
keratinocyte differentiation	6	6.8×	0.015	SPRR1B, SPRR3, TGM3, TP63, POU2F3, NFKBIZ
nucleotide-binding oligomerization domain containing 2 signaling pathway	3	21.0×	0.018	TLR4, INAVA, IRGM
positive regulation of interleukin-6 production	7	5.3×	0.018	STAT3, TLR4, CARD9, SPHK2, IFIH1, RIGI, INAVA
defense response to virus	11	3.5×	0.018	STAT2, CD40, IKBKE, IL23A, CARD9, IFNLR1, IFIH1, RIGI (+3 more)
response to muramyl dipeptide	3	19.2×	0.020	TNFAIP3, CARD9, INAVA

Therapeutics

Drugs indicated for this disease

42 approved, 20 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Acitretin	Approved (phase 4)
Adalimumab	Approved (phase 4)
Apremilast	Approved (phase 4)
Bergapten	Approved (phase 4)
Betamethasone Dipropionate	Approved (phase 4)
Bimekizumab	Approved (phase 4)
Brodalumab	Approved (phase 4)
Calcipotriene	Approved (phase 4)
Calcitriol	Approved (phase 4)
Clobetasol Propionate	Approved (phase 4)
Coal Tar	Approved (phase 4)
Cyclosporine	Approved (phase 4)
Desoximetasone	Approved (phase 4)
Dexamethasone	Approved (phase 4)
Dimethyl Fumarate	Approved (phase 4)
Efalizumab	Approved (phase 4)
Etanercept	Approved (phase 4)
Etretinate	Approved (phase 4)
Fluocinolone Acetonide	Approved (phase 4)
Fumaric Acid	Approved (phase 4)
Guselkumab	Approved (phase 4)
Halobetasol Propionate	Approved (phase 4)
Hydrocortisone	Approved (phase 4)
Infliximab	Approved (phase 4)
Isopropyl Alcohol	Approved (phase 4)
Ixekizumab	Approved (phase 4)
Methotrexate	Approved (phase 4)
Methoxsalen	Approved (phase 4)
Prednisolone	Approved (phase 4)
Prednisone	Approved (phase 4)
Risankizumab	Approved (phase 4)
Roflumilast	Approved (phase 4)
Salicylic Acid	Approved (phase 4)
Secukinumab	Approved (phase 4)
Spesolimab	Approved (phase 4)
Tacalcitol	Approved (phase 4)
Tapinarof	Approved (phase 4)
Tazarotene	Approved (phase 4)
Tildrakizumab	Approved (phase 4)
Trioxsalen	Approved (phase 4)
Ustekinumab	Approved (phase 4)
Zinc Oxide	Approved (phase 4)
Acetylcysteine	Phase 3 (in late-stage trials)
Alefacept	Phase 3 (in late-stage trials)
Atorvastatin	Phase 3 (in late-stage trials)
Betamethasone	Phase 3 (in late-stage trials)
Briakinumab	Phase 3 (in late-stage trials)
Certolizumab Pegol	Phase 3 (in late-stage trials)
Cyanocobalamin	Phase 3 (in late-stage trials)
Ebdarokimab	Phase 3 (in late-stage trials)
Gumokimab	Phase 3 (in late-stage trials)
Metformin	Phase 3 (in late-stage trials)
Mirikizumab	Phase 3 (in late-stage trials)
Mufemilast	Phase 3 (in late-stage trials)
Pefcalcitol	Phase 3 (in late-stage trials)
Piclidenoson	Phase 3 (in late-stage trials)
Tacrolimus Anhydrous	Phase 3 (in late-stage trials)
Tofacitinib	Phase 3 (in late-stage trials)
Vitamin E	Phase 3 (in late-stage trials)
Voclosporin	Phase 3 (in late-stage trials)
Vunakizumab	Phase 3 (in late-stage trials)
Zasocitinib	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Abatacept, Abrocitinib, Alitretinoin, Baricitinib, Belumosudil, Bermekimab, Bexarotene, Brepocitinib, Cholecalciferol, Clobetasol, Crisaborole, Cromolyn, Delgocitinib, Dimethicone, Doxercalciferol, Erlotinib, Fludarabine, Fluphenazine Decanoate, Fluphenazine Enanthate, Hyaluronidase (Human Recombinant), Hypericin, Icotinib, Imsidolimab, Indigo, Itacitinib, Izokibep, Ketoconazole, Lestaurtinib, M-1095, Masitinib, Mometasone Furoate, Mycophenolate Mofetil, Niacinamide, Nortriptyline, Olive Oil, Paclitaxel, Peficitinib, Petrolatum, Pioglitazone, Ponesimod, Riboflavin, Rimegepant, Rose Bengal Free Acid, Ruxolitinib, Sitagliptin, Sodium Chloride, Teriparatide Acetate, Thalidomide, Triamcinolone, Triamcinolone Acetonide, Urea.

Drug target analysis

Approved (phase 4): 16 · Phase ≥3: 16 · Phased (≥1): 19 · Undrugged: 56

Druggability breadth: 99 of 250 evidence-associated genes (40%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
RORC	DIGOXIN
RPS26	GENTAMICIN SULFATE
RPS6KA4	FEDRATINIB
RPS6KB1	FEDRATINIB
RUNX1	APOMORPHINE HYDROCHLORIDE
SDC4	BRIGATINIB
STAT3	MOMELOTINIB
STK11	FEDRATINIB
TLR4	METHOTREXATE
TYK2	FEDRATINIB
IKZF3	POMALIDOMIDE
HDAC7	CELECOXIB
IKBKE	MOMELOTINIB
CAMK2G	MOMELOTINIB
CASR	CINACALCET HYDROCHLORIDE
PAK5	FEDRATINIB

Top cohort targets by molecule count

Symbol	Molecules	Max phase
TYK2	72	4
RPS6KB1	39	4
CAMK2G	39	4
IKBKE	35	4
RPS6KA4	34	4
HDAC7	28	4
STAT3	18	4
STK11	17	4
PAK5	11	4
CASR	10	4

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
DIGOXIN	4	RORC, STAT3
TRETINOIN	4	RORC
ALITRETINOIN	4	RORC
GENTAMICIN SULFATE	4	RPS26
FEDRATINIB	4	CAMK2G, IKBKE, PAK5, RPS6KA4, RPS6KB1, STK11
RUXOLITINIB	4	CAMK2G, IKBKE, PAK5, RPS6KA4, TYK2
NINTEDANIB	4	IKBKE, PAK5, RPS6KA4, RPS6KB1, STK11, TYK2
SUNITINIB	4	CAMK2G, IKBKE, PAK5, RPS6KA4, RPS6KB1, STK11
ERLOTINIB	4	RPS6KA4, TYK2
MIDOSTAURIN	4	CAMK2G, IKBKE, RPS6KA4, RPS6KB1, STK11, TYK2
GEFITINIB	4	CAMK2G, RPS6KA4
SORAFENIB	4	RPS6KB1
VANDETANIB	4	RPS6KB1
BOSUTINIB	4	CAMK2G, IKBKE, RPS6KB1, TYK2
CRIZOTINIB	4	IKBKE, RPS6KB1, SDC4, TYK2
APOMORPHINE HYDROCHLORIDE	4	RUNX1
BRIGATINIB	4	CAMK2G, SDC4
MOMELOTINIB	4	CAMK2G, IKBKE, STAT3, TYK2
NITAZOXANIDE	4	STAT3
NICLOSAMIDE	4	STAT3
BARICITINIB	4	CAMK2G, STAT3, TYK2
DIGITOXIN	4	STAT3
DEUCRAVACITINIB	4	STAT3, TYK2
PACRITINIB	4	IKBKE, STK11, TYK2
METHOTREXATE	4	TLR4
POLYMYXIN B	4	TLR4
CARVEDILOL	4	TLR4
TOFACITINIB	4	TYK2
UPADACITINIB	4	TYK2
FILGOTINIB	4	TYK2

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 14.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
HDAC7	1,710	Binding:1695, ADMET:10, Functional:4, Toxicity:1
STAT3	1,319	Binding:1304, Functional:12, Unclassified:2, ADMET:1
TYK2	1,083	Binding:1043, Functional:39, ADMET:1
RORC	758	Binding:707, Functional:50, Unclassified:1
RPS6KB1	585	Binding:582, Functional:2, ADMET:1
RPS6KA4	389	Binding:387, Functional:1, ADMET:1
IKBKE	359	Binding:356, Functional:2, ADMET:1
CAMK2G	291	Binding:290, Functional:1
TLR4	267	Binding:254, Functional:10, ADMET:3
STK11	244	Binding:244
PAK5	217	Binding:217
IKZF3	101	Binding:100, Functional:1
RPS26	89	Binding:89
CASR	45	Functional:32, Binding:13
STAT2	24	Binding:24
TNFRSF1A	24	Binding:23, Functional:1
RUNX1	20	Binding:17, Functional:3
TGM3	15	Binding:15
TNFRSF9	11	Binding:11
CD40	10	Binding:10
CAPZB	9	Binding:9
CD40LG	8	Binding:8
SON	7	Binding:7
RNF114	6	Binding:6
BTD	3	Binding:3
TYRP1	3	Binding:3
BACH2	3	Binding:3
BRAP	2	Binding:2
TARBP1	2	Binding:2
FASLG	2	Binding:2
UBE2L3	2	Binding:2
SDC4	1	Binding:1
SPRR3	1	Binding:1
TNFAIP3	1	Binding:1
UBASH3A	1	Binding:1
SLC39A11	1	Binding:1
B3GNT2	1	Binding:1

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
RPS6KB1	2.7.11.1	non-specific serine/threonine protein kinase
BTD	3.5.1.12	biotinidase
STK11	2.7.11.1	non-specific serine/threonine protein kinase
SUOX	1.8.3.1	sulfite oxidase
TARBP1	2.1.1.34	tRNA (guanosine18-2’-O)-methyltransferase
ACO1	4.2.1.3	aconitate hydratase
TGM3	2.3.2.13	protein-glutamine gamma-glutamyltransferase
TYK2	2.7.10.2	non-specific protein-tyrosine kinase
UBE2L3	2.3.2.23, 2.3.2.24	E2 ubiquitin-conjugating enzyme, (E3-independent) E2 ubiquitin-conjugating enzyme
GLYAT	2.3.1.13, 2.3.1.71	glycine N-acyltransferase, glycine N-benzoyltransferase
HDAC7	3.5.1.98	histone deacetylase
IKBKE	2.7.11.10	IkappaB kinase
CAMK2G	2.7.11.17	Ca2+/calmodulin-dependent protein kinase
PAK5	2.7.11.1, 2.7.12.2	non-specific serine/threonine protein kinase, mitogen-activated protein kinase kinase

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
RORC	758
RPS6KA4	389
RPS6KB1	585
STAT3	1,319
STK11	244
TLR4	267
TYK2	1,083
IKZF3	101
HDAC7	1,710
IKBKE	359
CAMK2G	291
PAK5	217

Pharmacogenomics

Cohort genes with a PharmGKB record: 74; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

27 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Compound	Max phase	Cohort target (bioactivity)
DIGOXIN	4	RORC, STAT3
TRETINOIN	4	RORC
ALITRETINOIN	4	RORC
GENTAMICIN SULFATE	4	RPS26
FEDRATINIB	4	CAMK2G, IKBKE, PAK5, RPS6KA4, RPS6KB1, STK11
NINTEDANIB	4	IKBKE, PAK5, RPS6KA4, RPS6KB1, STK11, TYK2
SUNITINIB	4	CAMK2G, IKBKE, PAK5, RPS6KA4, RPS6KB1, STK11
ERLOTINIB	4	RPS6KA4, TYK2
MIDOSTAURIN	4	CAMK2G, IKBKE, RPS6KA4, RPS6KB1, STK11, TYK2
GEFITINIB	4	CAMK2G, RPS6KA4
SORAFENIB	4	RPS6KB1
VANDETANIB	4	RPS6KB1
BOSUTINIB	4	CAMK2G, IKBKE, RPS6KB1, TYK2
CRIZOTINIB	4	IKBKE, RPS6KB1, SDC4, TYK2
APOMORPHINE HYDROCHLORIDE	4	RUNX1
BRIGATINIB	4	CAMK2G, SDC4
MOMELOTINIB	4	CAMK2G, IKBKE, STAT3, TYK2
NITAZOXANIDE	4	STAT3
NICLOSAMIDE	4	STAT3
BARICITINIB	4	CAMK2G, STAT3, TYK2
DIGITOXIN	4	STAT3
DEUCRAVACITINIB	4	STAT3, TYK2
PACRITINIB	4	IKBKE, STK11, TYK2
POLYMYXIN B	4	TLR4
CARVEDILOL	4	TLR4
UPADACITINIB	4	TYK2
FILGOTINIB	4	TYK2

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	16	RORC, RPS26, RPS6KA4, RPS6KB1, RUNX1, SDC4, STAT3, STK11, TLR4, TYK2 (+6 more)
B	Phased (≥1) drug, not yet approved	3	SON, TGM3, TNFRSF1A
C	Druggable family + PDB, no drug	6	SUOX, TARBP1, ACO1, UBASH3A, UBE2L3, CSMD1
D	Druggable family + AlphaFold only, no drug	3	BTD, GLYAT, OR2W5
E	Difficult family or no structure, no drug	47	RGS6, RUNX3, CCL21, XCL1, BRAP, SLIT1, SNAI1, BSN, SPRR1B, SPRR3 (+37 more)

Undrugged target profiles

56 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
STAT2	24	TYK2
TNFRSF6B	0	TNFRSF1A
FASLG	2	TNFRSF1A
RGS6	0	—
RUNX3	0	—
CCL21	0	—
XCL1	0	—
BRAP	2	—
SLIT1	0	—
SNAI1	0	—
BSN	0	—
BTD	3	—
SPRR1B	0	—
SPRR3	1	—
SUOX	0	—
TARBP1	2	—
ELOA	0	—
ACO1	0	—
MYRF	0	—
TNFAIP3	1	—
TNFRSF14	0	—
CD40	10	—
TNFRSF9	11	—
TNFSF15	0	—
TNFSF18	0	—
CD40LG	8	—
TNFSF8	0	—
TNP2	0	—
TSC1	0	—
EIPR1	0	—

Clinical trials & evidence

Clinical trials

Clinical trials: 1,154.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	410
PHASE2	188
PHASE3	171
PHASE4	143
PHASE1	139
PHASE1/PHASE2	25
EARLY_PHASE1	15
PHASE2/PHASE3	9

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03240809	PHASE4	ACTIVE_NOT_RECRUITING	An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects
NCT03827876	PHASE4	RECRUITING	Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis
NCT03987763	PHASE4	RECRUITING	A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis
NCT04119102	PHASE4	RECRUITING	Duobrii in Combination With Biologics
NCT04347473	PHASE4	RECRUITING	ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis.
NCT04372277	PHASE4	RECRUITING	Taltz in Combination With Enstilar for Psoriasis
NCT05004727	PHASE4	RECRUITING	Multi-Center PAMPA Study
NCT05185258	PHASE4	ACTIVE_NOT_RECRUITING	Residual Disease MEMory in PSOriasis Skin During EnstiLAR® and Narrow-band Ultraviolet B Therapy: The MEMPSOLAR Study
NCT05270733	PHASE4	RECRUITING	Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics
NCT06857942	PHASE4	RECRUITING	A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
NCT07149792	PHASE4	RECRUITING	A Multi-center RCT Clinical Trial on Personalized Precision Medicine for Patients With Psoriasis and Psoriatic Arthritis and Investigation on Cardiovascular Biomarkers
NCT07352566	PHASE4	NOT_YET_RECRUITING	Utilization of a Microdevice for Psoriasis and Atopic Dermatitis
NCT07401992	PHASE4	RECRUITING	Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis
NCT07432386	PHASE4	NOT_YET_RECRUITING	Methotrexate Versus Apremilast for Pruritus in Psoriasis
NCT07432815	PHASE4	RECRUITING	Treatment of Psoriasis With Depression and/or Anxiety With Methotrexate vs Combined Methotrexate and Antidepressant
NCT07485764	PHASE4	NOT_YET_RECRUITING	Metformin Combined With Secukinumab for Moderate-to-Severe Plaque Psoriasis in Overweight or Obese Chinese Patients
NCT07487831	PHASE4	NOT_YET_RECRUITING	The Impact of Salt Intake on Sodium in the Skin and Inflammatory Skin Disease
NCT00096980	PHASE4	COMPLETED	A Study to Evaluate Raptiva in Combination With Topical Psoriasis Therapies
NCT00110981	PHASE4	COMPLETED	Utilization of Narrow Band Ultraviolet B (UVB) Light Therapy and Etanercept for the Treatment of Psoriasis
NCT00111124	PHASE4	COMPLETED	Enbrel® in Psoriatic Arthritis
NCT00150930	PHASE4	UNKNOWN	Home UVB Phototherapy for Psoriasis: Effectiveness, Quality of Life and Cost-Effectiveness
NCT00161655	PHASE4	COMPLETED	Study Evaluating Etanercept and Methotrexate in Plaque Psoriasis
NCT00195507	PHASE4	COMPLETED	Study Evaluating Etanercept in the Treatment of Subjects With Psoriasis
NCT00249808	PHASE4	COMPLETED	A Study of Efalizumab in Participants With Moderate to Severe Chronic Psoriasis Who Have Failed, Have a Contraindication to, or Are Intolerant of Other Systemic Therapies
NCT00287118	PHASE4	COMPLETED	A Multicentre, Open Label Phase IIIb/IV Study of Subcutaneously Administered Raptiva in the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis
NCT00312026	PHASE4	COMPLETED	A Study to Evaluate the Safety and Efficacy of Efalizumab in Adult Patients With Plaque Psoriasis Involving the Hands and/or Feet
NCT00332332	PHASE4	COMPLETED	Canadian Assessment of Patient Outcomes and Effectiveness of Etanercept (Enbrel) in Psoriasis
NCT00336973	PHASE4	COMPLETED	A Study to Evaluate Raptiva in Subjects With Chronic Moderate or Worse Plaque Psoriasis Who Have Had an Inadequate Response to an Anti-TNF Agent
NCT00436540	PHASE4	COMPLETED	A Comparison Between Clobetasol Propionate 0.05% (Clobex®) Spray and Clobetasol Propionate 0.05% (Olux®) Foam
NCT00437619	PHASE4	COMPLETED	A Study of Sequential Treatment With Daivobet (Betamethasone Dipropionate Plus Calcipotriol) and Daivonex (Calcipotriol) in Patients With Psoriasis.
NCT00462072	PHASE4	COMPLETED	Centocor Microarray Study of Patients
NCT00581165	PHASE4	COMPLETED	Study Evaluating Safety of Etanercept in Treatment of Patients With Moderate to Severe Psoriasiswith Etanercept
NCT00581555	PHASE4	COMPLETED	Evaluation of Etanercept in Patients With Plaque Psoriasis After Stopping Ciclosporin Therapy
NCT00655564	PHASE4	COMPLETED	Long-Term One Year Use of Alefacept (Amevive®) in Moderate to Severe Chronic Plaque Type Psoriasis
NCT00663052	PHASE4	COMPLETED	Study Evaluating Etanercept for the Treatment of Moderate to Severe Psoriasis
NCT00669123	PHASE4	COMPLETED	Chondroitin Sulphate Efficay/Safety in Patients With Knee Osteoarthritis and Psoriasis
NCT00669214	PHASE4	COMPLETED	A Study to Evaluate the Safety and Efficacy of Efalizumab in Adult Patients With Moderate to Severe Plaque Psoriasis With Involvement of the Scalp
NCT00686595	PHASE4	COMPLETED	A Study to Evaluate the Switch From Etanercept to Infliximab in Subjects With Moderate-to-Severe Psoriasis (Study P05133)
NCT00697034	PHASE4	TERMINATED	Effects of Capsaicin on the Structure, Distribution, and Function of Cutaneous Small Nerve Fibers in Psoriatic Skin
NCT00723437	PHASE4	COMPLETED	Evaluation of the Efficacy of Acitretin Therapy for Nail Psoriasis

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
ETANERCEPT	4	54
CRAVACITINIB	4	38
CALCIPOTRIENE	4	28
APREMILAST	4	26
RISANKIZUMAB	4	26
TOFACITINIB	4	25
USTEKINUMAB	4	23
GUSELKUMAB	4	20
SECUKINUMAB	4	20
BRODALUMAB	4	16
CLOBETASOL PROPIONATE	4	13
ACITRETIN	4	11
EFALIZUMAB	4	11
IXEKIZUMAB	4	11
ADALIMUMAB	4	9
TAPINAROF	4	9
INFLIXIMAB	4	8
METHOTREXATE	4	7
ALEFACEPT	4	6
HALOBETASOL PROPIONATE	4	6
CALCITRIOL	4	5
DESOXIMETASONE	4	5
RUXOLITINIB	4	5
TILDRAKIZUMAB	4	5
CRISABOROLE	4	4
MIRIKIZUMAB	4	4
ROFLUMILAST	4	4
BETAMETHASONE VALERATE	4	3
BIMEKIZUMAB	4	3
CERTOLIZUMAB PEGOL	4	3